Jordyn Sava

Treatment with futibatinib is now available for patients with previously treated, unresectable, locally advanced or metastatic intrahepatic FGFR2-muatant cholangiocarcinoma.

In the biomarker analysis of the phase 3 NeoALTTO study, a small reduction in antimüllerian hormone levels were seen during 2 weeks of anti-HER2 treatment alone followed by a significant decline in most patients with HER2-positive breast cancer after combining with weekly paclitaxel.

Despite achieving the co-primary end points, the phase 3 PRESERVE trial of trilaciclib in patients with metastatic colorectal cancer will be terminated.

Neeta Somaiah, MD, discusses her presentation given at the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium.

The partial clinical hold was put on the phase 1/2 VELA study after visual adverse events were observed in some patients with solid tumors after treatment with BLU-222.

In an interview with Targeted Oncology, Zev A. Wainberg, MD, discussed the rationale behind NAPOLI 3 and how findings from the study will influence the metastatic pancreatic ductal adenocarcinoma space moving forward.

In phase 1 of the KOMET-001 trial, ziftomenib showed a 30% complete response rate in patients with NPM1-mutant acute myeloid leukemia treated at a dose of 600 mg. This is now the recommended phase 2 dose for the phase 2 portion of the study.

CINtec PLUS Cytology is the only dual-stain triage test to be offered by BioReference Health LLC for patients with a high-risk human papillomavirus result.

In an interview with Targeted Oncology, Tara Seery, MD, discussed the rationale and findings from cohort 3 of the QUILT 88 study in metastatic pancreatic cancer.

Updated findings from a phase 2 study have further confirmed the benefit of olutasidenib when used as a treatment option for patients with IDH1-mutant relapsed/refractory acute myeloid leukemia.

Based on findings from the ROSALIA study, the FDA has accepted for review a proposed denosumab biosimilar for patients with osteoporosis and treatment-related bone loss in patients with cancer.

In a study examining racial disparities, differences in curative intent, endocrine and/or chemotherapy, frequency and types of treatment-related adverse events, and more were seen in Non-Hispanic Black women vs Non-Hispanic White women with breast cancer.

Wellmarker Bio’s novel therapeutic antibody WM-A1-3389 will be tested with Merck’s pembrolizumab in a phase 1b study of patients with non–small cell lung cancer.

Dermalyser shows the potential to decrease the workload for dermatologists and replace it with an artificial intelligence tool to identify malignant melanomas among cutaneous lesions.

In an interview with Targeted Oncology, Jeremy Abramson, MD, discussed findings of the phase 3 TRANSFORM study which were presented at the 2022 American Society of Hematology Annual Meeting.

Early findings from the phase 2 OATH trial show treatment with ONA-XR plus anastrozole elicits a 4-month progression- free survival rate of 77% and overall response rate of 22% in patients with HR-positive metastatic endometrial cancer.

The UPGRADE-A trial assessing the combination of upifitamab rilsodotin and carboplatin in patients with platinum-sensitive high-grade serous ovarian cancer has initiated the dose-expansion portion of the study.

The dose and titration of ropeginterferon alfa-2b is safe and effective for patients with polycythemia vera. However, additional studies are needed to provide rationale for an amended, higher initial dosage, and rapid titration.

While project GENIE provides public access to the representation of cancer distribution among racial and ethnic minorities, findings suggest its data does not reflect the true landscape of patients with cancer and may misrepresent the disease burden across patient populations.

In an interview with Targeted Oncology, Andrew Kuykendall, MD, discussed the most recent approvals for MPNs, practice changing abstracts presented at ASH 2022, and what he expects to see in 2023.

Based on findings from the phase 2 CARDAMON studies, further research is needed to explore deferred autologous hematopoietic stem-cell transplantation in some subgroups of patients with multiple myeloma.

The phase 3 NRG-GY018 trial of pembrolizumab and standard of care chemotherapy led to a clinically meaningful improvement in progression-free survival vs standard of care alone in endometrial carcinoma regardless of mismatch repair status.

Positive data from 2 phase 2 studies, SUMMIT and MutHER, have led to the addition of neratinib as a monotherapy or in combination to the National Comprehensive Cancer Network Guidelines for patients with breast cancer.

The phase 1/2 LUMINOS-103 trial will evaluate the intravesical instillation of lerapolturev in a cohort of patients with non-muscle-invasive bladder cancer.

In an interview with Targeted Oncology, Kathryn Beckermann, MD, PhD, discussed her talk from the International Kidney Cancer Symposium: North America 2022 on risk stratifications and considerations for improving outcomes for patients with renal cell carcinoma.

As requested by the FDA, a new biologics license application including updated scientific rationale has been submitted for remestemcel-L as treatment for patients with steroid-refractory acute graft-vs-host disease.

Based on findings from the phase 3 SORAYA trial, mirvetuximab soravtansine gained FDA approval for the treatment of patients with folate receptor alpha-high platinum-resistant ovarian cancer.

In an interview with Targeted Oncology, Laura Dawson, MD, FRCPC, discussed the results of the phase 3 NRG/RTOG 1112 study of SBRT followed by sorafenib compared with sorafenib alone in locally advanced hepatocellular carcinoma.

The first-in-class PPT-1 inhibitor ezurpimtrostat has been granted an orphan drug designation by the FDA for patients with hepatocellular carcinoma.

A first-in-human, multicenter, phase 1 clinical trial will begin to assess the safety, and biomarkers for response of DK210 in patients with advanced solid cancer who are overexpressing EGFR.